Valuation: Evotec SE

Market Cap 499M 559M 461M 418M 784M 53.13B 795M 5.56B 2.2B 27.8B 2.1B 2.05B 87.77B P/E 2026 *
-2.2x
P/E 2027 * -6.53x
Enterprise Value 642M 719M 593M 538M 1.01B 68.33B 1.02B 7.14B 2.83B 35.76B 2.7B 2.64B 113B EV / Sales 2026 *
1.07x
EV / Sales 2027 * 0.92x
Free-Float
89.91%
Yield 2026 *
-
Yield 2027 * -
1 day-1.06%
1 week+11.16%
Current month-9.35%
1 month+0.14%
3 months-18.83%
6 months-50.57%
Current year-48.44%
1 week 2.5
Extreme 2.5
2.92
1 month 2.41
Extreme 2.406
3.14
Current year 2.41
Extreme 2.406
6.73
1 year 2.41
Extreme 2.406
7.3
3 years 2.41
Extreme 2.406
21.69
5 years 2.41
Extreme 2.406
45.3
10 years 2.41
Extreme 2.406
45.83
Manager TitleAgeSince
Chief Executive Officer 55 01/07/2024
Director of Finance/CFO - 01/05/2026
Chief Operating Officer - 01/05/2026
Director TitleAgeSince
Director/Board Member 58 19/06/2019
Director/Board Member 64 01/06/2021
Director/Board Member 59 10/06/2024
Date Insider Type Main position Quantity % Market Cap. Importance
20/5/26 Exercice

Chief Technology Officer

12,462 0.0070%
4/5/26 Buy 15,510 0.0087%
4/5/26 Buy

Head of Human Resources

15,228 0.0086%
Change 5-day change 1-year change 3-year change Capi.($)
-1.06%+11.16%-58.22%-83.47% 566M
+2.41%-6.33%+43.43%+71.02% 63.29B
-0.15%+3.11%+10.29%+72.56% 54.89B
+0.57%+4.64%+12.82%+89.79% 53.28B
+0.37%+3.07%+28.23%+51.53% 45.81B
-1.21%+0.95%+20.44%+128.58% 43.46B
-0.37%-1.20%+252.94%+568.54% 40.23B
+0.05%+6.75%+14.48%+56.75% 33.45B
+1.19%-5.84%+27.86%-0.65% 23.7B
-0.38%+4.55%+37.71%+28.10% 23.76B
Average +0.14%+1.53%+39.00%+98.27% 38.24B
Weighted average by Cap. +0.38%+0.57%+48.01%+121.81%

Financials

2026 *2027 *
Net sales 599M 671M 553M 502M 939M 63.7B 953M 6.66B 2.63B 33.33B 2.52B 2.46B 105B 721M 808M 666M 604M 1.13B 76.74B 1.15B 8.02B 3.17B 40.16B 3.03B 2.97B 127B
Net income -222M -249M -205M -186M -348M -23.61B -353M -2.47B -977M -12.36B -933M -913M -39.01B -48.25M -54.04M -44.57M -40.42M -75.69M -5.13B -76.79M -537M -212M -2.69B -203M -198M -8.48B
Net Debt 143M 160M 132M 120M 224M 15.2B 227M 1.59B 628M 7.95B 600M 588M 25.1B 162M 182M 150M 136M 254M 17.25B 258M 1.8B 713M 9.03B 681M 667M 28.5B
Projected Income Statement - Annual - Evotec SE
Logo Evotec SE
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Employees
4,461
Date Price Change Volume
23/10/26 €2.810 -1.06% 885,925
22/10/26 €2.840 -0.63% 698,867
21/10/26 €2.858 +5.00% 1,544,082
20/10/26 €2.722 +3.50% 1,088,420
19/10/26 €2.630 +2.49% 856,856
Trader
Investor
Global
Quality
ESG MSCI
AAA
MarketScreener Ratings - Evotec SE
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
2.810EUR
Average target price
4.443EUR
Spread / Average Target
+58.11%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Evotec SE